News & Events
Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA – November 24, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive...
Swanbridge Capital invests in Immagene
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in...
Curie Capital invests in Allero Therapeutics
3 October 2019 Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform...
Allero Therapeutics secures seed investment from Swanbridge Capital
ROTTERDAM, 17 April 2019 – Swanbridge Capital, an early-stage Life Sciences venture capital fund, today announced the closing of a Seed investment in Allero Therapeutics, a biopharmaceutical company focused on the discovery and development of novel immunotherapies....
DegenRx secures funding for Alzheimer’s disease gene therapy
DegenRx secures funding for Alzheimer’s disease gene therapy
Swanbridge Capital invests in IPaDiC
Swanbridge Capital announced it invested in IPaDiC, a private company developing an implantable insulin pump for diabetes type 1 patients with an insulin resistance.
Abegaill successfully closes seed funding round
Abegaill B.V. announces the successfully closing of a seed funding round. This funding is provided by Swanbridge Capital, a Dutch life science venture capital fund, and Leander Healthcare, a Benelux medtech innovation provider.
Swanbridge Capital leads investment round into FABPulous
Swanbridge Capital, a Dutch Life Science Venture Capital fund, today announced its investment in FABPulous B.V., a Dutch start-up company focused on the development of a new diagnostic tool that quickly distinguishes whether patients with chest pains are at urgent risk of a heart attack. Swanbridge Capital co-led the investment round together with Health Innovations.
Launch of €6.5 million Life Sciences Fund
Swanbridge Capital today announced the launch and closing of its first life science fund. The fund, with a size of €6.5 million, will invest in early stage life sciences ventures that require capital to fund their first Proof of Concept experiments.
Swanbridge Capital
Brainpark II - Building XI
Lichtenauerlaan 40
3062 ME Rotterdam
info@swanbridgecapital.nl